De Sousa Linhares, Annika
Battin, Claire
Jutz, Sabrina
Leitner, Judith
Hafner, Christine
Tobias, Joshua http://orcid.org/0000-0002-0961-5306
Wiedermann, Ursula http://orcid.org/0000-0002-1302-3223
Kundi, Michael http://orcid.org/0000-0002-2707-3213
Zlabinger, Gerhard J. http://orcid.org/0000-0002-7478-4173
Grabmeier-Pfistershammer, Katharina http://orcid.org/0000-0003-0665-5414
Steinberger, Peter http://orcid.org/0000-0001-6848-4097
Article History
Received: 12 February 2019
Accepted: 23 July 2019
First Online: 7 August 2019
Competing Interests
: C. Hafner reports personal fees from Bristol-Myers Squibb, Amgen, Merck Sharp & Dohme, Roche, and Novartis and nonfinancial support from Bristol-Myers Squibb, Merck Sharp & Dohme, Roche and Pierre Fabre outside the submitted work. G.J. Zlabinger reports personal fees from Alexion, Bristol-Myers Squibb, MedAhead, the Austrian Chamber of Physicians, Pfizer, UCB Pharma, Merck Sharp & Dohme, GlaxoSmithKline, and AbbVie outside the submitted work. P. Steinberger reports personal fees from Bristol-Myers Squibb outside the submitted work. All other authors declare no potential conflicts of interest.